By Ewen Callaway
They say good news comes in threes. For the third time in a week, a coronavirus vaccine developer has reported preliminary results suggesting its vaccine is highly effective.
Today, biotech company Moderna in Cambridge, Massachusetts, reported that its RNA-based vaccine was more than 94% effective at preventing COVID-19, based on an analysis of 95 cases in its ongoing phase III efficacy trial.
But scientists say that the press-released results share a few more details than last week’s positive announcements from Pfizer and BioNtech, which are together working on a rival RNA vaccine, and from Russian developers behind the controversial ‘Sputnik V’ vaccine. Moderna released figures suggesting that its vaccine was likely to prevent severe COVID-19 infections, something that was not clear from the other developers’ announcements.
“We need to see the peer-reviewed data, but by any standards, this looks like more very good news,” says Daniel Altmann, an immunologist at Imperial College London.
Continue reading by clicking the name of the source below.